QL1706-Based Therapy Post-PD-1/L1 Failure in Advanced Endometrial Cancer

"* Drug: QL1706: 5 mg/kg IV every 3 weeks until progression, unacceptable toxicity, completion of 1 year of treatment, or meeting protocol-defined discontinuation criteria, whichever occurred first.~* Drug: Chemotherapy: physician's choice chemotherapy for 3-6 cycles.~* Drug: Bevacizumab (optional): 15 mg/kg IV every 3 weeks until progression, unacceptable toxicity, completion of 1 year of treatment, or meeting protocol-defined discontinuation criteria, whichever occurred first."